2023-06-05 05:56:11 ET
- Navidea Biopharmaceuticals ( NYSE: NAVB ) said it received a notice from the NYSE American for not being in compliance with a rule for continued listing on the exchange.
- The NYSE notice stated that company’s common stock had been trading for a low price per share for a substantial period of time.
- The NYSE decided that continued listing was based on the company showing sustained price improvement in reasonable time or effecting a reverse stock split, which the NYSE staff determined to be until Dec. 1, and could be extended to the company's next annual meeting in 2023, Navidea noted.
- Navidea added that it intends to regain compliance with the rules.
- The company noted that it remains subject to conditions mentioned in the NYSE American's letters dated January 28, 2022 and April 8, 2022 for stockholders' equity noncompliance.
- NAVB -7.95% to $0.096 premarket June 5
For further details see:
Navidea gets NYSE non-compliance notice, stock falls